BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12470805)

  • 1. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities.
    Blass JP
    Neurobiol Aging; 2002; 23(6):1077-84. PubMed ID: 12470805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abeta conformational change is central to Alzheimer's disease.
    Holtzman DM
    Neurobiol Aging; 2002; 23(6):1085-8. PubMed ID: 12470806
    [No Abstract]   [Full Text] [Related]  

  • 3. Testing times for the "amyloid cascade hypothesis".
    Hardy J
    Neurobiol Aging; 2002; 23(6):1073-4. PubMed ID: 12470803
    [No Abstract]   [Full Text] [Related]  

  • 4. Amyloid-beta: a (life) preserver for the brain.
    Obrenovich ME; Joseph JA; Atwood CS; Perry G; Smith MA
    Neurobiol Aging; 2002; 23(6):1097-9. PubMed ID: 12470809
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioflocculant hypothesis: a partial endorsement.
    Terry R
    Neurobiol Aging; 2002; 23(6):1075. PubMed ID: 12470804
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolution and the scientific method.
    Tucker HM; Estus S
    Neurobiol Aging; 2002; 23(6):1093-5. PubMed ID: 12470808
    [No Abstract]   [Full Text] [Related]  

  • 7. Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease.
    Robinson SR; Bishop GM
    Neurobiol Aging; 2002; 23(6):1051-72. PubMed ID: 12470802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is amyloid beta-peptide neurotoxic or neuroprotective and what is its role in the binding of metal ions?
    Savory J; Ghribi O; Herman MM
    Neurobiol Aging; 2002; 23(6):1089-92. PubMed ID: 12470807
    [No Abstract]   [Full Text] [Related]  

  • 9. The amyloid hypothesis: let sleeping dogmas lie?
    Bishop GM; Robinson SR
    Neurobiol Aging; 2002; 23(6):1101-5. PubMed ID: 12470810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
    Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
    J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism.
    Gandy S; Petanceska S
    Biochim Biophys Acta; 2000 Jul; 1502(1):44-52. PubMed ID: 10899430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.
    Wirths O; Multhaup G; Czech C; Blanchard V; Moussaoui S; Tremp G; Pradier L; Beyreuther K; Bayer TA
    Neurosci Lett; 2001 Jun; 306(1-2):116-20. PubMed ID: 11403971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease.
    Huichalaf CH; Al-Ramahi I; Park KW; Grunke SD; Lu N; de Haro M; El-Zein K; Gallego-Flores T; Perez AM; Jung SY; Botas J; Zoghbi HY; Jankowsky JL
    Hum Mol Genet; 2019 Jun; 28(12):2014-2029. PubMed ID: 30753434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
    DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
    Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-life stress lastingly alters the neuroinflammatory response to amyloid pathology in an Alzheimer's disease mouse model.
    Hoeijmakers L; Ruigrok SR; Amelianchik A; Ivan D; van Dam AM; Lucassen PJ; Korosi A
    Brain Behav Immun; 2017 Jul; 63():160-175. PubMed ID: 28027926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-truncated Aβ
    Wirths O; Walter S; Kraus I; Klafki HW; Stazi M; Oberstein TJ; Ghiso J; Wiltfang J; Bayer TA; Weggen S
    Alzheimers Res Ther; 2017 Oct; 9(1):80. PubMed ID: 28978359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1δE9 mouse model of Alzheimer's disease.
    Singh BK; Vatsa N; Kumar V; Shekhar S; Sharma A; Jana NR
    Hum Mol Genet; 2017 Oct; 26(20):4042-4054. PubMed ID: 29016862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions.
    van Groen T; Liu L; Ikonen S; Kadish I
    Neuroscience; 2003; 119(4):1185-97. PubMed ID: 12831872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.